Key result
Digitalis has limited potency as an antiarrhythmic drug for atrial fibrillation and flutter, though its low cost and ease of administration justify its use as initial treatment.
Why the study?
Does digitalis effectively manage atrial fibrillation and flutter?
Does digitalis effectively manage atrial fibrillation and flutter?
While digitalis is cost-effective and easy to administer for atrial fibrillation and flutter, its limited antiarrhythmic potency suggests newer drugs may be more useful.
Answers are grounded in this paper and cite their sources.
Supports digitalis as initial AF therapy where cost and simplicity matter; leaves open comparative efficacy versus modern agents in prospective trials.
PreviewDigitalis has long been used as an antiarrhythmic drug in treatment of paroxysmal supraventricular tachycardia, atrial fibrillation and flutter, and arrhythmias associated with congestive heart failure. However, newer evidence indicates that this cardiac glycoside has limited potency as an antiarrhythmic drug. In this review, the authors describe the effect of digitalis on cardiovascular function in management of atrial fibrillation and flutter. They conclude that while widespread use of digitalis as initial treatment for these supraventricular arrhythmias is justified by its low cost, ease of administration, and relatively few noncardiac side effects, newer drugs may ultimately prove more useful.
No takes yet. Share an insight, caveat, or question.
Simpson et al. (1986) conducted a review in Atrial fibrillation and flutter. Digitalis vs. Newer drugs was evaluated. Digitalis has limited potency as an antiarrhythmic drug for atrial fibrillation and flutter, though its low cost and ease of administration justify its use as initial treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: